Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions - Full Text View

Sponsor:	Novartis Pharmaceuticals
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00067080

Purpose

The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.

Condition	Intervention	Phase
Anemia, Sickle Cell	Drug: ICL670 Drug: deferoxamine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis

Resource links provided by NLM:

Genetics Home Reference related topics: sickle cell disease

MedlinePlus related topics: Anemia Blood Transfusion and Donation Sickle Cell Anemia

Drug Information available for: Deferoxamine Deferasirox Deferoxamine mesylate

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Evaluate the safety and tolerability of multiple doses if ICL670

Secondary Outcome Measures:

Estimate the absolute and relative change of liver iron content (LIC) and total body iron excretion (TBIE)
Evaluate the pharmacokinetics
Evaluate the relationship between pharmacokinetics, pharmacodynamics and safety variables
Evaluate the relationship between hepatic iron and potential surrogate markers

Estimated Enrollment:	170
Study Start Date:	May 2003
Estimated Study Completion Date:	December 2003

Detailed Description:

Patients who require repeated blood transfusions accumulate iron in the body as blood cells contain iron and there is no natural body mechanism to eliminate it. After a while the iron levels get high enough to be toxic to the body. The current therapy of choice is deferoxamine which does a good job of removing excess iron, but is difficult to administer. Deferoxamine requires subcutaneous (under the skin) infusions over 4 to 8 hours nightly 3 to 7 nights per week. In addition to the need to wear an infusion pump nightly, adverse reactions around the site of the injection are frequent.

Eligibility

Ages Eligible for Study:	2 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age greater than or equal to 2 years
Sickle cell disease patients already treated with or suitable for treatment with deferoxamine 20 to 40 mg/kg/day
Serum ferritin greater than 1000 mg/ml
Liver iron content greater than 2 mg iron/g dw assessed by means of superconducting quantum interference device (SQUID) for patients who receive simple transfusions and greater than 5 mg iron/ g dw for patients who receive exchange transfusions or who have a history of intermittent blood transfusion.
Regular transfusion aimed at maintaining % Hb A above 50% or a previous history of simple transfusion being the recipient of at least 20 units of packed red blood cells.

Exclusion Criteria:

Chronic anemias other than sickle cell disease
Documented toxicity to deferoxamine
Elevated liver enzymes in the year preceeding enrollment
Active hepatitis B or hepatitis C
HIV seropositivity
Elevated serum creatinine or significant proteinuria
History of nephrotic syndrome
Uncontrolled systemic hypertension
Fever and other signs/symptoms of infection within 10 days prior to the start of the study
Presence of clinically relevant cataract or previous history of clinically relevant ocular toxicity related to iron chelation
Second or third degree AV block, clinically relevant Q-T interval prolongation, or patients requiring digoxin or other drugs that prolong the Q-T interval (other than beta-adrenergic receptor blocking agents).
Diseases (cardiovascular, renal, hepatic, etc.) that would prevent the patient from undergoing any of the treatment options
Psychiatric or addictive disorders that would prevent the patient from giving informed consent
History of drug or alcohol abuse within the 12 months prior to the study
Pregnant or breast feeding patients
Patients treated with systemic investigational drugs within 4 weeks or topical investigational drugs within 7 days before the start of the study
Patients who require concomitant therapy with hydroxyurea
Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug, such as gastrointestinal disease or major surgery, renal disease, difficulty voiding or urinary obstruction, or impaired pancreatic function
Non-compliant or unreliable patients
Patients unable to undergo any study procedures such as the hearing or eye tests, or the liver echocardiography
Patients unable to undergo SQUID examination

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067080

Hide Study Locations

Locations

United States, Alabama
U. of S. Alabama Medical Center
Mobile, Alabama, United States, 36604
United States, California
Children's Hospital & Research Center
Oakland, California, United States, 94609
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Loma Linda University Medical Center
Loma Linda, California, United States, 92354
United States, Colorado
Colorado Sickle Cell Treatment and Research Center
Denver, Colorado, United States, 80262
United States, District of Columbia
Howard University Hospital
Washington, District of Columbia, United States, 20059
United States, Florida
Tampa Children's Hospital at St Joseph's
Tampa, Florida, United States, 33607
United States, Georgia
Adult Sickle Cell Clinic, Medical College of Georgia
Augusta, Georgia, United States, 30912
Georgia Comprehensive Sickle cell Center, Grady Hospital
Atlanta, Georgia, United States, 30335
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
United States, Louisiana
Tulane University Sickle Cell Center
New Orleans, Louisiana, United States, 70112
Children's Hospital, Department of Hematology/Oncology
New Orleans, Louisiana, United States, 70118
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
Children's Hospital Boston, Division of Hematology/Oncology
Boston, Massachusetts, United States, 02115
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, New York
NY Methodist Hospital
Brooklyn, New York, United States, 11215
Sickle Cell Center, Montefiore Hospital
Bronx, New York, United States, 10467
U. Of Rochester Medical Center
Rochester, New York, United States, 14642
Weill Medical College of Cornell University
New York, New York, United States, 10021
United States, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
United States, Ohio
Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
James Cancer Hospital
Columbus, Ohio, United States, 43210
Barrett Center, University of Cincinnati
Cincinnati, Ohio, United States, 45219
United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Santee Hematology/Oncology
Sumter, South Carolina, United States, 29150
Palmetto Health Clinical Trials
Columbia, South Carolina, United States, 29203
Liberty Hematology Oncology Center
Columbia, South Carolina, United States, 29203
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Scott and White Memorial Hospital & Clinics
Temple, Texas, United States, 76508
Texas Children's Hospital/Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Virginia
Children's Hospital of the King's Daughter
Norfolk, Virginia, United States, 23507

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

Study Chair:

Novartis

More Information

No publications provided

Study ID Numbers:	CICL670A0109
Study First Received:	August 11, 2003
Last Updated:	November 18, 2009
ClinicalTrials.gov Identifier:	NCT00067080 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

Sickle cell disease
iron overload
deferoxamine
hemosiderosis

Additional relevant MeSH terms:

Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Hematologic Diseases
Deferasirox
Iron Chelating Agents
Anemia
Anemia, Hemolytic
Iron Metabolism Disorders
Pharmacologic Actions

Siderophores
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hemosiderosis
Hemoglobinopathies
Chelating Agents
Iron Overload
Anemia, Sickle Cell
Deferoxamine

ClinicalTrials.gov processed this record on November 27, 2009